Fig. 4.

Paclitaxel decreased anti-β₂-glycoprotein I/β₂-glycoprotein I (anti-β₂GPI/β₂GPI)-induced Toll-like receptor (TLR)-4, myeloid differentiation factor 88 (MyD88) and myeloid differentiation protein 2 (MD-2) expression in THP-1 (human acute monocytic leukaemia) cells. The THP-1 cells were pretreated with paclitaxel (1 µM) for 1 h, then stimulated by anti-β₂GPI (10 µg/ml)/β₂GPI (100 µg/ml) complex, isotype control rabbit immunoglobulin G (R-IgG) (10 µg/ml)/β₂GPI (100 µg/ml) and lipopolysaccharide (LPS) (500 ng/ml) for 2 h (a) or 6 h (b). The mRNA levels and the protein expression of TLR-4 (a1, a2), MyD88 (b1, b2) and MD-2 (c1, c2) were detected by real-time quantitative reverse transcription–polymerase chain reaction (qRT–PCR) and Western blotting. Data shown are from three separate experiments. *P < 0·05 versus no paclitaxel-treated cells.